Phase III Study Failure Clouds Future Of Avanir’s Alzheimer’s Agitation Candidate
Executive Summary
Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.